Harmed patients deserve answers, not assumptions

A case we've been following closely involves Jimmie Wilson, a patient who suffered serious liver failure after receiving a compounded tirzepatide formulation. Her story is painful to read, and her suffering is real. But as APC's Scott Brunner wrote on LinkedIn this week, empathy doesn't require us to rush past the facts – and right now, the facts are still incomplete.

The cause of her liver injury hasn't been definitively established. Drug-induced liver injury is complex and multifactorial, and while there are documented case reports of liver injury associated with tirzepatide itself, the active ingredient is present in both FDA-approved and compounded versions. So could compounding be a factor? It's possible. Is it the cause? That hasn't been determined. Correlation is not causation, and that distinction matters enormously when the policy response to a single, still-unexplained case could affect patient access to compounded medications across the board.

The Kentucky State Board of Pharmacy will review what happened. That's the right process. What isn't, is drawing sweeping conclusions before the investigation is complete – and that goes for policymakers just as much as it does for the public. Patients who suffer harm deserve answers grounded in evidence. So does good policy.